The fourth in China! Investigational Tamiflu approved

Today, Tianshili released an enterprise announcement that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., has received the approval document for drug registration issued by the State Drug Administration and approved its listing Tadalafil is a selective and reversible phosphodiesterase 5 (PDE5) inhibitor, which is used to solve the problem of erectile dysfunction in men It has the characteristics of quick onset and long duration of efficacy, and is not affected by high-fat diet and alcohol intake In addition, tadalafil has two increased indications: prostatic hyperplasia and pulmonary hypertension Tadalafil was first developed by Lilly company in the United States In 2004, it was listed in the United States as a drug for the treatment of erectile dysfunction (ED) Its trade name is "Cialis" (hialy), and it was approved to be listed in China in 2005 Since then, Lilly has applied to FDA for two indications of pulmonary hypertension (PAH) and benign prostatic hyperplasia (BPH) and obtained approval Erectile dysfunction (ED) is a common male sexual dysfunction According to the published literature, the disease has a rapid growth trend The common risk factors of ED include aging, obesity, hypertension, cardiovascular disease, diabetes, lifestyle (drinking, smoking), social psychological factors (depression, behavioral anxiety), abnormal levels of sex hormones and spinal cord injury The incidence rate of aging related diseases such as coronary heart disease, diabetes mellitus and metabolic syndrome is increasing as human life prolongs Incidence rate of these diseases may continue to rise PDE5 inhibitors are recognized as the first-line drugs for ED treatment at home and abroad According to the hospital sales data of pharmaceutical intelligence data Enterprise Edition, in 2018, the sales volume of tadalafei tablet hospital, a domestic sample hospital, was 11.7733 million yuan, of which the main market share was occupied by the original research Lilly's "hilly" In addition, according to Yaozhi, in addition to Tianshili, which has just been approved, there are Qilu pharmaceutical, Nanjing Zhengda Tianqing and Changchun Haiyue, which have been approved In addition, according to the company's announcement, Tianshili has invested 8.1911 million yuan in the total R & D of tadalafei R & D project Now it has been approved as a new chemical medicine in 4 categories According to the relevant policies, it has passed the consistency evaluation, further enriched its product pipeline, improved its market competitiveness, and jointly challenged the original research enterprises with Qilu pharmaceutical and other enterprises to break the original research barriers and carve up China's huge domestic market 37 statement: This article is the integration content, the viewpoint only represents the author, does not represent the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.